RE:RE:RE:Conditions are right for biopharma M&A to break outMay 09, 2023 - Gilead's M&A activites carry on with the buyout of a private PARP inhibitor company XinThera. After deals with start-up MiroBio and Tmunity, Gilead is now further expanding beyond its HIV products with the acquisition of the oncology and inflammation start-up company XinThera, which is developing oral small molecule PARP inhibitors for various tumors.